ACT AZITHROMYCIN TABLET
国: カナダ
言語: 英語
ソース: Health Canada
製品の特徴
(SPC)
18-10-2016
この製品の一部のドキュメントは現在利用できません。カスタマーサービスにリクエストを送信できます。入手可能になり次第、お知らせします。
リクエストを送信します。
リクエストを送信します。
有効成分:
AZITHROMYCIN (AZITHROMYCIN MONOHYDRATE)
から入手可能:
ACTAVIS PHARMA COMPANY
ATCコード:
J01FA10
INN（国際名）:
AZITHROMYCIN
投薬量:
250MG
医薬品形態:
TABLET
構図:
AZITHROMYCIN (AZITHROMYCIN MONOHYDRATE) 250MG
投与経路:
ORAL
パッケージ内のユニット:
6/30/100
処方タイプ:
Prescription
治療領域:
OTHER MACROLIDES
製品概要:
Active ingredient group (AIG) number: 0126072001; AHFS:
認証ステータス:
CANCELLED POST MARKET
承認日:
2018-06-12
製品の特徴
_ _
_Page 1 of 66 _
PRODUCT MONOGRAPH
Pr
ACT AZITHROMYCIN
Azithromycin Tablets USP
250 mg and 600 mg
Antibiotic
Actavis Pharma Company
6733 Mississauga Road, Suite 400
Mississauga, Ontario
L5N 6J5
Date of Revision:
October 07, 2016
Control No: 198611
_ _
_Page 2 of 66 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................3
SUMMARY PRODUCT INFORMATION
.........................................................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................................................
3
CONTRAINDICATIONS
..................................................................................................................................
5
WARNINGS AND PRECAUTIONS
..................................................................................................................
5
ADVERSE REACTIONS
...................................................................................................................................
9
DRUG INTERACTIONS
.................................................................................................................................
15
DOSAGE AND ADMINISTRATION
..............................................................................................................
19
OVERDOSAGE
...............................................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
.............................................................................................
21
STORAGE AND STABILITY
.........................................................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
...............................................................................
24
PART II: SCIENTIFIC INFORMATION
..........................................................
完全なドキュメントを読む
